ArticleInflammopharmacology2026
Pimenta racemosa extract ameliorates chemically induced ulcerative colitis in rats by suppressing inflammation and oxidative stress.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemical Profiling ofPharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pimenta racemosa (P. racemosa) tree leaves are used in traditional medicine to alleviate flatulence and gastrointestinal disorders. Ulcerative colitis (UC) is a gastrointestinal inflammatory disease with well-known inflammatory and immunoregulatory pathological features. The complexity of the disease requires multi-targeted treatment. Because of their relative safety and effectiveness, natural products can be utilized as adjunct and alternative agents to conventional UC treatment. So, the present work aimed to isolate phenolic constituents of the plant’s 80% aqueous methanol extract (AME) and evaluate its protective effect on acetic acid-induced ulcerative colitis (UC) in rats. The defatted AME was chromatographed, and structures of the isolated compounds were elucidated using UV, NMR spectroscopy and HPLC–ESI–MS analysis. Induction of ulcerative colitis was done using Acetic acid, the protective effect against ulcerative colitis was supported by histopathological and immunohistochemical examinations. The isolated compounds are Kaempferol 3-O-β-D-glucopyranoside (kaempferol 3-O-glucoside) or (Astragalin) (1), quercetin 3-O-β-D-glucopyranoside (Isoquercetrin) (2), Quercetin (3), Catechin (4), quercetin 3-O-α-L-rhamnospyranoside (Quercetrin) (5). The AME of P. racemosa significantly alleviated the UC by decreasing the disease activity index and Wallace score. Additionally, GSH, CAT, and SOD were increased, and MDA was decreased, suggesting AME’s antioxidant activity. The decreased levels of WBCs, neutrophils, TNF-α, IL-1β, IL-6, MPO, and NF-κB p65 support the AME’s anti-inflammatory properties. The highest activity was recorded for the dose of 1000 mg/kg. These findings were in harmony with the histopathological examination and the Alcian Blue staining for mucin content. The current study revealed that the AME of P. racemosa has protective activities against UC in rats via its antioxidant and anti-inflammatory properties may be attributed to its phenolic profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.